Hepatic Steatosis
Mostrando 1-12 de 137 artigos, teses e dissertações.
-
1. Risk factors associated with nonalcoholic fatty liver disease evaluated by elastography in patients with type 2 diabetes
ABSTRACT Objective: There is controversy about the indication for nonalcoholic fatty liver disease (NAFLD) screening in patients with type 2 diabetes mellitus (T2D). The present study aims to contribute to NAFLD surveillance in patients with T2D, assessing the association of clinical and biological variables with hepatic stiffness and steatosis. Subjects a
Archives of Endocrinology and Metabolism. Publicado em: 2022
-
2. Trajectory of NAFLD characteristics after Roux-en-Y gastric bypass: a five-year historical cohort study
Abstract BACKGROUND: The long-term effects of bariatric surgery on the course of non-alcoholic fatty hepatopathy (NAFLD) are not fully understood. OBJECTIVE: To analyze the evolution of NAFLD characteristics through noninvasive markers after Roux-en-Y gastric bypass (RYGB) over a five-year period. DESIGN AND SETTING: Historical cohort study; tertiary-leve
Sao Paulo Medical Journal. Publicado em: 2022
-
3. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome: associated factors and noninvasive fibrosis staging in a single Brazilian center
ABSTRACT Objective Polycystic ovary syndrome (PCOS) is a recognized risk factor for nonalcoholic fatty liver disease (NAFLD). The aims of this study were to investigate the prevalence and factors associated with NAFLD in women with PCOS and evaluate noninvasive indices of hepatic fibrosis in patients with PCOS and NAFLD. Subjects and methods Patients with
Arch. Endocrinol. Metab.. Publicado em: 2020-06
-
4. Ultrasound elastography in patients with fatty liver disease
Resumo Esteatose hepática ocorre pelo acúmulo de lipídios nos hepatócitos, sua cronificação cursa com inflamação lobular e evolui com fibrose hepática, cirrose e carcinoma hepatocelular. O diagnóstico precoce do acometimento hepático é desejável em razão da melhor resposta terapêutica dos pacientes na fase inicial da doença. O exame físico n
Radiol Bras. Publicado em: 25/11/2019
-
5. SARCOPENIA AND SEVERITY OF NON-ALCOHOLIC FATTY LIVER DISEASE
RESUMO CONTEXTO: A doença hepática gordura não-alcoólica caracteriza-se pela deposição de lipídios no parênquima hepático, excedendo 5% do peso do fígado na ausência de outras afecções como hepatites virais, alcoólicas ou doenças metabólicas. A doença hepática gordura não-alcoólica tem sido observada como a forma mais comum de doença h
Arq. Gastroenterol.. Publicado em: 14/10/2019
-
6. Sericin as treatment of obesity: morphophysiological effects in obese mice fed with high-fat diet
RESUMO Objetivo Investigar os efeitos da sericina extraída de casulos de Bombyx mori na morfofisiologia de camundongos com obesidade induzida por dieta hiperlipídica. Métodos Camundongos machos C57Bl6, com 9 semanas de idade, foram distribuídos em Grupos Controle e Obeso, que receberam ração padrão para roedores ou dieta hiperlipídica por 10 semana
Einstein (São Paulo). Publicado em: 26/09/2019
-
7. High-Lard and High-Cholesterol Diet, but not High-Lard Diet, Leads to Metabolic Disorders in a Modified Dyslipidemia Model
Resumo Fundamento: Tendo em vista o aumento da prevalência global de doenças cardiovasculares e hepáticas, o conteúdo lipídico da dieta e sua relação com o acúmulo de gordura nos hepatócitos têm sido investigados como fatores-chave na prevenção dessas doenças. Objetivo: Avaliar os efeitos metabólicos de uma dieta rica em banha suplementada co
Arq. Bras. Cardiol.. Publicado em: 29/08/2019
-
8. Alterations in the Transcriptional Profile of the Liver Tissue and the Therapeutic Effects of Propolis Extracts in Alcohol-induced Steatosis in Rats
Abstract Abstract: The hepatoprotective effects of the ethanolic extracts of propolis (EEP) on alcohol-induced liver steatosis were investigated in Wistar rats. Chronic alcoholic fatty liver was induced by administration of 52% alcohol to male Wistar rats at the dose of 1% body weight for 7 weeks. Then animals were simultaneously treated with 50% ethanol sol
An. Acad. Bras. Ciênc.. Publicado em: 12/08/2019
-
9. PREVALENCE OF HEPATIC STEATOSIS AMONG CHILDREN AND ADOLESCENTS WITH CYSTIC FIBROSIS AND ITS ASSOCIATION WITH NUTRITIONAL STATUS
RESUMO Objetivo: Determinar a prevalência de esteatose hepática (EH) em crianças e adolescentes com fibrose cística (FC) e associá-la com o estado nutricional. Métodos: Estudo transversal com crianças e adolescentes com diagnóstico de FC. Foram aferidos o peso e a altura para o cálculo do índice de massa corpórea (IMC) e classificação do est
Rev. paul. pediatr.. Publicado em: 19/06/2019
-
10. Ursodeoxycholic acid in the prevention of gallstones in patients subjected to Roux-en-Y gastric bypass
Abstract Purpose: To evaluate the contribution of ursodeoxycholic acid (UDCA) in the first 12 months after Roux-en-Y gastric bypass in the prevention of gallstone formation. Methods: A community-based clinical trial was conducted. A total of 137 patients were included in the study; 69 were treated with UDCA, starting 30 days after the surgery, at a dose of
Acta Cir. Bras.. Publicado em: 14/02/2019
-
11. α-Linolenic acid prevents hepatic steatosis and improves glucose tolerance in mice fed a high-fat diet
OBJECTIVES: Dietary omega-3 fatty acids have been efficacious in decreasing serum cholesterol levels and reducing the risk of cardiovascular disease. However, the metabolic and molecular changes induced by the omega-3 fatty acid α-linolenic acid (ALA), which is found in linseed oil, are not fully understood. In this study, we showed a correlation between A
Clinics. Publicado em: 29/10/2018
-
12. Exenatide ameliorates hepatic steatosis and attenuates fat mass and FTO gene expression through PI3K signaling pathway in nonalcoholic fatty liver disease
Non-alcoholic fatty liver disease (NAFLD) is a common disease associated with metabolic syndrome and can lead to life-threatening complications like hepatic carcinoma and cirrhosis. Exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist antidiabetic drug, has the capacity to overcome insulin resistance and attenuate hepatic steatosis but the specific
Braz J Med Biol Res. Publicado em: 14/06/2018